Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Roche insists Spark deal is still on, despite lacklustre take-upShareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension Share XRoche insists Spark deal is still on, despite lacklustre take-uphttps://pharmaphorum.com/news/roche-insists-spark-deal-still-on-despite-lacklustre-take-up/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Novartis snaps up ex-US partnership with Spark on gene therapyI was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was Share XNovartis snaps up ex-US partnership with Spark on gene therapyhttps://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/
Can Spark make a profit on its groundbreaking gene therapy?Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the Share XCan Spark make a profit on its groundbreaking gene therapy?https://pharmaphorum.com/news/can-spark-make-profit-groundbreaking-gene-therapy/
